| Species |
Human |
| Protein Construction |
TRAIL R1/DR4/TNFRSF10A (Pro34-Asn239)_x000D_
Accession # O00220 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human TRAIL, No Tag at 5μg/ml (100μl/well) on the plate can bind TRAIL R1/DR4/TNFRSF10A hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
48.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations. |
| Synonyms |
DR4; CD261; TNFRSF10A; TRAIL-R; APO2; TRAIL R1; MGC9365 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
